Skip to main content
. Author manuscript; available in PMC: 2024 Sep 26.
Published in final edited form as: Int J Cancer. 2021 Jul 31;149(9):1713–1722. doi: 10.1002/ijc.33739

Table 3. MAGMA gene analyses for individual toxicities.

Toxicity Treatment group Gene P-value Validation chemo P-value Validation cetuximab status P-value Pooled
P-value
Neutropenia FOLFOX RPL17-C18orf32 8.9 × 10−7   .57 .53 —
C18orf32 1.3 × 10−6   .56 .51 —
RPL17 1.5 × 10−6   .56 .52 —
XELOX MROH5 6.6 × 10 −7 3.3 × 10 −2 .09 3.7 × 10 −7
Stomatitis FOLFOX SCAF4 1.3 × 10−6   .07 .61 —
Vomiting XELOX LRRC69 1.2 × 10−7   .77 .73 —
SLC26A7 4.3 × 10−7   .81 .60 —
PIP4P2 9.7 × 10−7   .94 .34 —

Note: Significance was set at a Bonferroni-corrected significance threshold of P < 2.5 × 10−6. Only MROH5 was significantly associated with neutropenia in patients treated with XELOX and was independently validated in patients receiving XELOX + cetuximab (P = 3.3 × 10−2), with a pooled P = 3.7 × 10−7 (in bold) (and P = 5.8 × 10−7 when also including the FOLFOX cohort).

Abbreviations: Validation cetuximab status, Validation in the COIN and COIN-B group with the alternative chemotherapy regimen but with the same cetuximab status; Validation chemo, validation in the COIN and COIN-B group with the same chemotherapy regimen but alternative cetuximab status.